CDH17 Car T therapy has blockbuster potential, page-4

I should also point out that:

- FDA has approved seamless transition from Phase 1 to Phase 2 subject to efficacy signals without stopping the trial between phases

- Car T registrations have historically been allowed after Phase 2 (not Phase 3), which reduces the cost and timelines but tens of millions and many years

- FDA fast track designation is a given if there are efficacy signals

- First patient dosing is imminent ie any day now